Abstract
BACKGROUND: This study aimed to explore the predictive value of CHA(2) DS(2) -VASc score for in-hospital major adverse cardiac events (MACEs) in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary artery intervention. METHODS: A total of 746 STEMI patients were divided into four groups according to CHA(2) DS(2) -VASc score (1, 2-3, 4-5, >5). The predictive ability of the CHA(2) DS(2) -VASc score for in-hospital MACE was made. Subgroup analysis was made between gender differences. RESULTS: In a multivariate logistic regression analysis model including creatinine, total cholesterol, and left ventricular ejection fraction, CHA(2) DS(2) -VASc score was an independent predictor of MACE as a continuous variable (adjusted odds ratio: 1.43, 95% confidence interval [CI]: 1.27-1.62, p < .001). As a category variable, using the lowest CHA(2) DS(2) -VASc score of 1 as a reference, CHA(2) DS(2) -VASc score 2-3, 4-5, >5 groups for predicting MACE was 4.62 (95% CI: 1.94-11.00, p = .001), 7.74 (95% CI: 3.18-18.89, p < .001), and 11.71 (95% CI: 4.14-33.15, p < .001). The CHA(2) DS(2) -VASc score was also an independent risk factor for MACE in the male group, either as a continuous variable or category variable. However, CHA(2) DS(2) -VASc score was not a predictor of MACE in the female group. The area under the curve value of the CHA(2) DS(2) -VASc score for predicting MACE was 0.661 in total patients (74.1% sensitivity and 50.4% specificity [p < .001]), 0.714 in the male group (69.4% sensitivity and 63.1% specificity [p < .001]), but there was no statistical significance in the female group. CONCLUSIONS: CHA(2) DS(2) -VASc score could be considered as a potential predictor of in-hospital MACE with STEMI, especially in males.